Skip to main content

Advertisement

Table 1 Demographics and clinical characteristics of patients with cancer-related pain who were treated with controlled-release oxycodone/naloxone (OXN-CR) or controlled-release oxycodone (OX-CR) (full analysis set, FAS)

From: Efficacy and safety of controlled-release oxycodone/naloxone versus controlled-release oxycodone in Korean patients with cancer-related pain: a randomized controlled trial

Variable OXN-CR OX-CR P value
Total (cases) 58 59  
Age, years [cases (%)]    0.297
 ≥70 17 (29.3) 11 (18.6)  
 <70 41 (70.7) 48 (81.4)  
Sex [cases (%)]    0.343
 Male 43 (74.1) 39 (66.1)  
 Female 15 (25.9) 20 (33.9)  
Cancer type [cases (%)]a    NA
 Colorectal 24 (41.4) 23 (39.0)  
 Gastric 10 (17.2) 8 (13.6)  
 Lung 6 (10.3) 5 (8.5)  
 Pancreatic/hepatic bile duct 6 (10.3) 9 (15.3)  
 Prostate 2 (3.4) 3 (5.1)  
 Esophageal 3 (5.2) 1 (1.7)  
 Others 8 (13.8) 11 (18.6)  
Metastasis [cases (%)]    0.990
 Yes 57 (98.3) 58 (98.3)  
 No 1 (1.7) 1 (1.7)  
Prior analgesic use (number of times of administration)b NA
 Strong opioids 23 22  
 Weak opioids 39 39  
 NSAID/acetaminophen 11 12  
 Adjuvant analgesicsc 1 0  
 Other medicationsd 1 0  
  1. NSAID non-steroidal anti-inflammatory drug, NA not applicable
  2. aThe percentage in either group does not add up to 100% because one patient in the OXN-CR group had colorectal cancer and sarcoma and one patient in the OX-CR group had gastric cancer and lung cancer
  3. bAnalgesics were administered 2–6 months prior to the screening visit
  4. c“Adjuvant analgesics” (pregabalin) was administered once to one patient in the OXN-CR group
  5. d“Other medications” (codeine) was administered once to one patient in the OXN-CR group